SIGA

SIGA Technologies, Inc. is a publicly traded, commercial-stage pharmaceutical company focused on providing solutions for unmet needs in the health security market, including medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats as well as emerging infectious diseases. The company primarily develops drug solutions for some of the deadliest pathogens—smallpox, Ebola, dengue fever, Lassa fever, and other dangerous viruses. Its goal is to discover, develop, and commercialize drugs to prevent and treat these highly threatening conditions. The company's mission is to disarm devastating viral diseases and establish robust modern biodefense countermeasures.